Amgen announced the phase 3 DISCREET trial, which evaluated Otezla (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis, reached…
Krystal Biotech reported positive topline results from the pivotal phase 3 GEM-3 trial of beremagene geperpavec (B-VEC), now known as Vyjuvek, for the treatment of…
Connect Biopharma reported results from the global Phase 2 clinical trial of subcutaneously administered CBP-201 in adult patients with moderate-to-severe atopic dermatitis (AD). Although no…
UCB announced positive top-line interim analysis results from the Phase 3 BE OPTIMAL study assessing the efficacy and safety of Bimzelx (bimekizumab) in the treatment of…
Janssen announced comprehensive efficacy and safety data from the DISCOVER–2 trial of Tremfya (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
